NEWARK, DE | The lung cancer surgery market stands at USD 1.6 billion in 2026 and is forecast to reach USD 2.8 billion by 2036, expanding at a compound annual growth rate (CAGR) of 5.9%. This sustained expansion reflects the critical role of surgical intervention in oncology, particularly for resectable early-stage non-small cell lung cancer (NSCLC), where procedures deliver life-saving outcomes. Healthcare providers continue prioritizing precision, reduced complications, and improved recovery—factors that anchor demand for advanced surgical solutions in a market defined by quality and clinical reliability rather than high-volume fluctuations.

Read Full Report-https://www.futuremarketinsights.com/reports/lung-cancer-surgery-market

Market snapshot: global market 2026 - 2036

• Market size 2026? USD 1.6 billion
• Market size 2036? USD 2.8 billion
• CAGR? 5.9% (2026–2036)
• Leading application segment and share? Segmentectomy (40%) — favored for its minimally invasive profile and preservation of healthy lung tissue in early-stage or smaller localized tumors
• Leading end user and share? Hospitals (65%) — preferred for specialized facilities, advanced equipment, multidisciplinary teams, and comprehensive post-operative care
• Key growth regions? India (highest projected CAGR among tracked countries), followed by other emerging markets with rising healthcare infrastructure and diagnosis rates
• Top companies? Medtronic Plc., Asap Endoscopic Products, Ethicon Inc. (J&J), Germed USA Inc., Teleflex Incorporated, B. Braun Melsungen AG, Karl Storz, Richard Wolf, Olympus Medical Systems Corp, Intuitive Surgical Inc., PENTAX Medical Company, FUJIFILM Holdings Corporation, Ambu A/S

Market Momentum (YoY Path) 

The lung cancer surgery market follows a clear trajectory of steady compounding growth. Starting at USD 1.6 billion in 2026, the market reaches approximately USD 2.3 billion by 2031 (reflecting an absolute increase of USD 700 million in the first half of the forecast period, fueled by accelerated uptake of minimally invasive and robotic-assisted techniques). Growth then continues at a moderated but consistent pace, climbing to USD 2.8 billion by 2036 (adding another USD 500 million from 2031 onward). Intermediate milestones include stronger momentum through 2028 and 2030 as early-detection programs and technology adoption build, followed by stabilization around 2033 and 2035 as mature markets integrate established innovations.

Why the Market is Growing 

Demand for lung cancer surgery remains anchored in the persistent global rise in lung cancer incidence, driven by ageing populations, tobacco exposure, air pollution, and other environmental risk factors. Early detection through improved screening (including low-dose CT) identifies more operable tumors, expanding the pool of patients eligible for resection. Adoption of minimally invasive approaches—such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted platforms—reduces recovery times, complications, and hospital stays, making surgery more attractive to both clinicians and patients. Ongoing advancements in imaging, diagnostics, and precision tools further reinforce surgical preference for suitable cases, while supportive reimbursement and healthcare infrastructure investments in emerging regions sustain long-term expansion.

Segment Spotlight

Application

 Segmentectomy commands the leading position with 40% share in the lung cancer surgery market. Its minimally invasive nature, ability to preserve healthy lung tissue, and suitability for early-stage or localized tumors make it especially valuable for patients with compromised pulmonary function. As detection improves and emphasis grows on reducing surgical risks while maintaining efficacy, segmentectomy continues to gain preference over more extensive resections.

End User 

Hospitals hold 65% of the lung cancer surgery market, driven by their capacity to manage complex procedures, provide specialized thoracic teams, deploy advanced equipment, and deliver full-spectrum perioperative and rehabilitation care. With rising lung cancer cases requiring expert handling of potential complications, hospitals remain the dominant setting for these high-stakes interventions.

Drivers, Opportunities, Trends, Challenges

Drivers

 Rising lung cancer incidence worldwide, expansion of early-detection screening programs, and clinical preference for procedures that improve survival and quality of life propel the lung cancer surgery market. Advances in minimally invasive platforms, robotic systems, and imaging support greater precision and encourage wider surgical adoption.

Opportunities 

Emerging markets offer substantial potential through improving healthcare access, growing surgical capacity, and increasing early diagnosis rates. Continued innovation in robotic and minimally invasive tools, along with supportive policies, creates room for expanded procedural volumes.

Trends 

Broader integration of robotic-assisted surgery, enhanced preoperative 3D planning, minimally invasive techniques, and enhanced recovery protocols are reshaping thoracic programs. Multidisciplinary tumor boards and real-world evidence registries further refine best practices and quality standards.

Challenges 

Late-stage diagnoses that render tumors inoperable shrink the eligible patient pool. Regional disparities in access to specialized centers, high costs of advanced systems, surgical risks in comorbid patients, variable reimbursement, and slower adoption of newer techniques in certain settings constrain faster expansion.

Country Growth Outlook (CAGR)

• India: 7%
• China: 6.7%
• UK: 6%
• Germany: 5.6%
• USA: 4%
• France: Not specified in source (aligned with developed Europe trends)
• Brazil: Not specified in source (emerging market potential noted broadly)

Competitive Landscape 

Leading players in the lung cancer surgery market include Medtronic Plc., Ethicon Inc. (J&J), Intuitive Surgical Inc., Olympus Medical Systems Corp, Karl Storz, and others such as Teleflex Incorporated, B. Braun Melsungen AG, Richard Wolf, PENTAX Medical Company, FUJIFILM Holdings Corporation, and Ambu A/S. These companies compete through innovation in surgical precision, minimally invasive instruments, robotic platforms, endoscopic systems, staplers, energy devices, and imaging solutions—focusing on improved outcomes, safety, and adoption of advanced thoracic techniques.

Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates: https://www.futuremarketinsights.com/reports/brochure/rep-gb-396

Request For Sample Report | Customize Report |purchase Full Report -https://www.futuremarketinsights.com/reports/sample/rep-gb-396  

Scope of the Report

• Quantitative Units: USD Billion (2026 base)
• Segmentation: Application (Segmentectomy, Lobectomy, Wedge Resection, Pneumonectomy); End User (Hospitals, Ambulatory Surgical Centers); Product (Thoracoscopes, Mediastinoscopes, Bronchoscopes, Robotic-Assisted Thoracic Surgery Systems, Surgical Staplers, Surgical Energy Instruments)
• Regions: North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia, Middle East & Africa
• Countries: United States, Canada, Mexico, Brazil, Argentina, Germany, France, United Kingdom, Italy, Spain, Netherlands, China, India, Japan, South Korea, ANZ, GCC Countries, South Africa (among others)
• Key Companies Profiled: Medtronic Plc., Asap Endoscopic Products, Ethicon Inc. (J&J), Germed USA Inc., Teleflex Incorporated, B. Braun Melsungen AG, Karl Storz, Richard Wolf, Olympus Medical Systems Corp, Intuitive Surgical Inc., PENTAX Medical Company, FUJIFILM Holdings Corporation, Ambu A/S

FAQ

What is the projected size of the lung cancer surgery market in 2036? The lung cancer surgery market is expected to reach USD 2.8 billion by 2036.

What is the forecast CAGR for the lung cancer surgery market from 2026 to 2036? The global lung cancer surgery market is projected to grow at a CAGR of 5.9% over the period.

Which application segment leads the lung cancer surgery market? Segmentectomy holds the leading share at 40%, driven by its minimally invasive benefits and tissue preservation advantages.

Which end user dominates the lung cancer surgery market? Hospitals capture 65% of the market thanks to specialized facilities, expertise, and comprehensive care capabilities.

Which country shows the highest projected CAGR in the lung cancer surgery market? India leads with a 7% CAGR (2026–2036), supported by rising incidence, improving infrastructure, and greater access to advanced techniques.

Source: Future Market Insights, Lung Cancer Surgery Market Forecast Outlook 2025–2035 (Last updated: 03 Jan 2026)

Explore More Related Studies Published by FMI Research:

Radiation-Free Fetal Heart Rate Monitor Market- https://www.futuremarketinsights.com/reports/radiation-free-fetal-heart-rate-monitor-market

Small Molecule CDMO Market- https://www.futuremarketinsights.com/reports/small-molecule-cdmo-market

Conversational AI in Healthcare Market- https://www.futuremarketinsights.com/reports/conversational-ai-in-healthcare-market

Endoscope Protective Barrier Covers Market- https://www.futuremarketinsights.com/reports/endoscope-protective-barrier-covers-market

Obesity GLP-1 Market- https://www.futuremarketinsights.com/reports/obesity-glp-1-market

About Future Market Insights (FMI)

 Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi

Contact Us:    

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@futuremarketinsights.com